Can plant biotechnology help break the HIV-malaria link?

Biotechnology Advances

Volumn 32, Issue 3, 2014, Pages 575-582

  Vamvaka, E ^a   Twyman, R M ^b   Christou, P ^a,c   Capell, T ^a  

^a UNIVERSITY OF LLEIDA   (Spain)

^b TRM Ltd   (United Kingdom)

^c INSTITUCIÓ CATALANA DE RECERCA I ESTUDIS AVANÇATS ICREA   (Spain)

Author keywords

Developing countries; HIV; Malaria; Plant biotechnology; Poverty diseases

Indexed keywords

BIOTECHNOLOGY; DEVELOPING COUNTRIES; MALARIA CONTROL; PUBLIC HEALTH;

ANTIMALARIAL DRUG; HIV; IMMUNOSUPPRESSIVE EFFECTS; MALARIA; OPPORTUNISTIC INFECTIONS; PLANT BIOTECHNOLOGY; SUB-SAHARAN AFRICA; SYNERGISTIC INTERACTION;

DISEASES;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; BIOTECHNOLOGY; DEVELOPING WORLD; DISEASE CONTROL; DISEASE PREVALENCE; DISEASE SEVERITY; ENDEMIC SPECIES; EPIDEMIOLOGY; HEALTH RISK; HUMAN IMMUNODEFICIENCY VIRUS; MALARIA; PLANT; POVERTY ALLEVIATION; PUBLIC HEALTH; TOXICITY; WOMENS HEALTH;

SUB-SAHARAN AFRICA;

HUMAN IMMUNODEFICIENCY VIRUS;

ANTIMALARIAL AGENT;

BIOTECHNOLOGY; COMPLICATION; DEVELOPING COUNTRY; HIV INFECTIONS; HUMAN; MALARIA; METABOLISM; TRANSGENIC PLANT;

ANTIMALARIALS; BIOTECHNOLOGY; DEVELOPING COUNTRIES; HIV INFECTIONS; HUMANS; MALARIA; PLANTS, GENETICALLY MODIFIED;

EID: 84900533954     PISSN: 07349750     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.biotechadv.2014.02.004     Document Type: Review

References (119)

1. Akanmori B.D., Kurtzhals J.A., Goka B.Q., Adabayeri V., Ofori M.F., Nkrumah F.K., et al. Distinct patterns of cytokine regulation in discrete clinical forms of Plasmodium falciparum malaria. Eur Cytokine Netw 2000, 11:113-118.
2. Alemu A., Shiferaw Y., Addis Z., Mathewos B., Birhan W. Effect of malaria on HIV/AIDS transmission and progression. Parasit Vectors 2013, 6:1756-3305.
3. Atzori C., Bruno A., Chichino G., Cevini C., Bernuzzi A.M., Gatti S., et al. HIV-1 and parasitic infections in rural Tanzania. Ann Trop Med Parasitol 1993, 87:585-593.
4. Bebell L.M., Gasasira A., Kiggundu M., Dokomajilar C., Kamya M.R., Charlebois E.D., et al. HIV-1 infection in patients referred for malaria blood smears at government health clinics in Uganda. J Acquir Immune Defic Syndr 2007, 46:624-630.
5. Berkley J.A., Bejon P., Mwangi T., Gwer S., Maitland K., Williams T.N., et al. HIV infection, malnutrition, and invasive bacterial infection among children with severe malaria. Clin Infect Dis 2009, 49:336-343.
6. Birku Y., Mekonnen E., Bjorkman A., Wolday D. Delayed clearance of Plasmodium falciparum in patients with human immunodeficiency virus co-infection treated with artemisinin. Ethiop Med J 2002, 40:17-26.
7. Bloland P.B., Wirima J.J., Steketee R.W., Chilima B., Hightower A., Breman J.G. Maternal HIV-infection and infant-mortality in Malawi - evidence for increased mortality due to placental malaria infection. AIDS 1995, 9:721-726.
8. Brahmbhatt H., Kigozi G., Wabwire-Mangen F., Serwadda M.D., Sewankambo N., Lutalo T., et al. The effects of placental malaria on mother-to-child HIV transmission in Rakai, Uganda. AIDS 2003, 17:2539-2541.
9. Brentlinger P.E., Behrens C.B., Micek M.A. Challenges in the concurrent management of malaria and HIV in pregnancy in sub-Saharan Africa. Lancet Infect Dis 2006, 6:100-111.
10. Chalwe V., Van geertruyden J.P., Mukwamataba D., Menten J., Kamalamba J., Mulenga M., et al. Increased risk for severe malaria in HIV-1-infected adults, Zambia. Emerg Infect Dis 2009, 15:749-858.
11. Chaudhuri A., Polyakova J., Zbrzezna V., Williams K., Gulati S., Pogo A.O. Cloning of glycoprotein D cDNA, which encodes the major subunit of the Duffy blood group system and the receptor for the Plasmodium vivax malaria parasite. Proc Natl Acad Sci U S A 1993, 90:10793-10797.
12. Chintu C., Luo C., Bhat G., DuPont H.L., Mwansa-Salamu P., Kabika M., et al. Impact of the human immunodeficiency virus type-1 on common pediatric illnesses in Zambia. J Trop Pediatr 1995, 41:348-353.
13. Clapham P.R., McKnight A. HIV-1 receptors and cell tropism. Br Med Bull 2001, 58:43-59.
14. Clemente M., Corigliano M.G. Overview of plant-made vaccine antigens against malaria. J Biomed Biotechnol 2012, 1-8.
15. Colebunders R., Bahwe Y., Nekwei W., Ryder R., Perriens J., Nsimba K., et al. Incidence of malaria and efficacy of oral quinine in patients recently infected with human-immunodeficiency-virus in Kinshasa, Zaire. J Infect 1990, 21:167-173.
16. Cuadros D.F., Branscum A.J., Crowley P.H. HIV-malaria co-infection: effects of malaria on the prevalence of HIV in East sub-Saharan Africa. Int J Epidemiol 2011, 40:e931-e939.
17. Cuadros D.F., Branscum A.J., Garcia-Ramos G. No evidence of association between HIV-1 and malaria in populations with low HIV-1 prevalence. PLoS ONE 2011, 6:e23458.
18. Cutbush M., Mollison P.L. The Duffy blood group system. Heredity 1950, 4:383-389.
19. Cutbush M., Mollison P.L., Parkin D.M. A new human blood group. Nature 1950, 165:188-198.
20. Davenport G.C., Ouma C., Hittner J.B., Were T., Ouma Y., Ong'echa J.M., et al. Hematological predictors of increased severe anemia in Kenyan children coinfected with Plasmodium falciparum and HIV-1. Am J Hematol 2010, 85:227-233.
21. Davoodi-Semiromi A., Schreiber M., Nalapalli S., Verma D., Singh N.D., Banks R.K., et al. Chloroplast-derived vaccine antigens confer dual immunity against cholera and malaria by oral or injectable delivery. Plant Biotechnol J 2010, 8:223-242.
22. Diallo A.H., Ki-Zerbo G., Sawadogo A.B., Guiguemde T.R. Severe malaria and HIV in adult patients in Bobo-Dioulasso, Burkina Faso. Med Trop (Mars) 2004, 64:345-350.
23. Diou J., Gauthier S., Tardif M.R., Fromentin R., Lodge R., Sullivan D.J., et al. Ingestion of the malaria pigment hemozoin renders human macrophages less permissive to HIV-1 infection. Virology 2009, 395:56-66.
24. Dooley K.E., Flexner C., Andrade A.S. Drug interactions involving combination antiretroviral therapy and other anti-infective agents: repercussions for resource-limited countries. J Infect Dis 2008, 198:948-961.
25. Drake P.M., Barbi T., Sexton A., McGowan E., Stadlmann J., Navarre C., et al. Development of rhizosecretion as a production system for recombinant proteins from hydroponic cultivated tobacco. FASEB J 2009, 23:3581-3589.
26. Durrani Z., McInerney T.L., McLain L., Jones T., Bellaby T., Brennan F.R., et al. Intranasal immunization with a plant virus expressing a peptide from HIV-1 gp41 stimulates better mucosal and systemic HIV-1-specific IgA and IgG than oral immunization. J Immunol Methods 1998, 220:93-103.
27. Eglen R.M., Boss R., Long G.S. Deja vu all over again: emerging concepts of g protein-coupled receptor (GPCR) function and drug discovery. DDW 2007, 8:69-78.
28. Este J.A., Greene W.C., Debyser Z., Ikeda Y., Freed E.O., Stephens E., et al. Novel targets for HIV therapy. Antiviral Res 2008, 80:251-265.
29. Farhi M., Marhevka E., Ben-Ari J., Algamas-Dimantov A., Liang Z., Zeevi V., et al. Generation of the potent anti-malarial drug artemisinin in tobacco. Nat Biotechnol 2011, 29:1072-1074.
30. Farrance C.E., Chichester J.A., Musiychuk K., Shamloul M., Rhee A., Manceva S.D., et al. Antibodies to plant-produced Plasmodium falciparum sexual stage protein Pfs25 exhibit transmission blocking activity. Hum Vaccin 2011, 7:191-198.
31. Farrance C.E., Rhee A., Jones R.M., Musiychuk K., Shamloul M., Sharma S., et al. A plant-produced Pfs230 vaccine candidate blocks transmission of Plasmodium falciparum. Clin Vaccine Immunol 2011, 18:1351-1357.
32. Fear G., Komarnytsky S., Raskin I. Protease inhibitors and their peptidomimetic derivatives as potential drugs. Pharmacol Ther 2007, 113:354-68.
33. Floss D.M., Sack M., Stadlmann J., Rademacher T., Scheller J., Stoger E., et al. Biochemical and functional characterization of anti-HIV antibody-ELP fusion proteins from transgenic plants. Plant Biotechnol J 2008, 6:379-391.
34. Floss D.M., Sack M., Arcalis E., Stadlmann J., Quendler H., Rademacher T., et al. Influence of elastin-like peptide fusions on the quantity and quality of a tobacco-derived human immunodeficiency virus-neutralizing antibody. Plant Biotechnol J 2009, 7:899-913.
35. Francesconi P., Fabiani M., Dente M.G., Lukwiya M., Okwey R., Ouma J., et al. HIV, malaria parasites, and acute febrile episodes in Ugandan adults: a case-control study. AIDS 2001, 15:2445-2450.
36. French N., Nakiyingi J., Lugada E., Watera C., Whitworth J.A.G., Gilks C.F. Increasing rates of malarial fever with deteriorating immune status in HIV-1-infected Ugandan adults. AIDS 2001, 15:899-906.
37. Ghosh S., Malhotra P., Lalitha P.V., Guha-Mukherjee S., Chauhan V.S. Expression of Plasmodium falciparum C-terminal region of merozoite surface protein (PfMSP1(19)), a potential malaria vaccine candidate, in tobacco. Plant Sci 2002, 162:335-343.
38. Grimberg B.T., Udomsangpetch R., Xainli J., McHenry A., Panichakul T., Sattabongkot J., et al. Plasmodium vivax invasion of human erythrocytes inhibited by antibodies directed against the Duffy binding protein. PLoS Med 2007, 4:e337.
39. Grimwade K., French N., Mbatha D.D., Zungu D.D., Dedicoat M., Gilks C.F. Childhood malaria in a region of unstable transmission and high human immunodeficiency virus prevalence. Pediatr Infect Dis J 2003, 22:1057-1063.
40. Grimwade K., French N., Mbatha D.D., Zungu D.D., Dedicoat M., Gilks C.F. HIV infection as a cofactor for severe falciparum malaria in adults living in a region of unstable malaria transmission in South Africa. AIDS 2004, 18:547-554.
41. Guerra C.A., Gikandi P.W., Tatem A.J., Noor A.M., Smith D.L., Hay S.I., et al. The limits and intensity of Plasmodium falciparum transmission: implications for malaria control and elimination worldwide. PLoS Med 2008, 5:38.
42. Hahn B.H., Shaw G.M., De Cock K.M., Sharp P.M. AIDS as a zoonosis: scientific and public health implications. Science 2000, 287:607-614.
43. He W., Neil S., Kulkarni H., Wright E., Agan B.K., Marconi V.C., et al. Duffy antigen receptor for chemokines mediates trans-infection of HIV-1 from red blood cells to target cells and affects HIV-AIDS susceptibility. Cell Host Microbe 2008, 4:52-62.
44. Hirt H., M'Pia B. Natural medicine in the tropics I: foundation text 2008, Winnenden, Germany, Anamed. 3rd ed.
45. Hoffman I.F., Jere C.S., Taylor T.E., Munthali P., Dyer J.R., Wirima J.J., et al. The effect of Plasmodium falciparum malaria on HIV-1 RNA blood plasma concentration. AIDS 1999, 13:487-494.
46. Hollak C.E. An evidence-based review of the potential benefits of taliglucerase alfa in the treatment of patients with Gaucher disease. Core Evid 2012, 7:15-20.
47. Horuk R., Chitnis C.E., Darbonne W.C., Colby T.J., Rybicki A., Hadley T.J., et al. A receptor for the malarial parasite Plasmodium vivax: the erythrocyte chemokine receptor. Science 1993, 261:1182-1184.
48. Inion I., Mwanyumba F., Gaillard P., Chohan V., Verhofstede C., Claeys P., et al. Placental malaria and perinatal transmission of human immunodeficiency virus type 1. J Infect Dis 2003, 188:1675-1678.
49. Jancova P., Anzenbacher P., Anzenbacherova E., Phase I.I. Drug metabolizing enzymes. Biomed Pap Olomouc 2010, 154:103-116.
50. Karasev A.V., Foulke S., Wellens C., Rich A., Shon K.J., Zwierzynski I., et al. Plant based HIV-1 vaccine candidate: Tat protein produced in spinach. Vaccine 2005, 23:1875-1880.
51. Khasnis A.A., Karnad D.R. Human immunodeficiency virus type 1 infection in patients with severe falciparum malaria in urban India. J Postgrad Med 2003, 49:114-117.
52. Kim T.G., Langridge W.H. Synthesis of an HIV-1 Tat transduction domain-rotavirus enterotoxin fusion protein in transgenic potato. Plant Cell Rep 2004, 22:382-387.
53. Kim T.G., Ruprecht R., Langridge W.H. Synthesis and assembly of a cholera toxin B subunit SHIV 89.6p Tat fusion protein in transgenic potato. Protein Expr Purif 2004, 35:313-319.
54. Kublin J.G., Patnaik P., Jere C.S., Miller W.C., Hoffman I.F., Chimbiya N., et al. Effect of Plasmodium falciparum malaria on concentration of HIV-1-RNA in the blood of adults in rural Malawi: a prospective cohort study. Lancet 2005, 365:233-240.
55. Kulkarni H., Marconi V.C., He W., Landrum M.L., Okulicz J.F., Delmar J., et al. The Duffy-null state is associated with a survival advantage in leukopenic HIV-infected persons of African ancestry. Blood 2009, 114:2783-2792.
56. Lau O.S., Ng D.W., Chan W.W., Chang S.P., Sun S.S. Production of the 42-kDa fragment of Plasmodium falciparum merozoite surface protein 1, a leading malaria vaccine antigen, in Arabidopsis thaliana seeds. Plant Biotechnol J 2010, 8:994-1004.
57. Loos A., Van Droogenbroeck B., Hillmer S., Grass J., Kunert R., Cao J., et al. Production of monoclonal antibodies with a controlled N-glycosylation pattern in seeds of Arabidopsis thaliana. Plant Biotechnol J 2010, 9:179-192.
58. Lotter-Stark H.C., Rybicki E.P., Chikwamba R.K. Plant made anti-HIV microbicides-a field of opportunity. Biotechnol Adv 2012, 30:1614-1626.
59. Ma J.K., Drake P.M., Christou P. The production of recombinant pharmaceutical proteins in plants. Nat Rev Genet 2003, 4:794-805.
60. Ma J.K., Barros E., Bock R., Christou P., Dale P.J., Dix P.J., et al. Molecular farming for new drugs and vaccines. Current perspectives on the production of pharmaceuticals in transgenic plants. EMBO Rep 2005, 6:593-599.
61. Ma C., Wang L., Webster D.E., Campbell A.E., Coppel R.L. Production, characterisation and immunogenicity of a plant-made Plasmodium antigen-the 19kDa C-terminal fragment of Plasmodium yoelii merozoite surface protein 1. Appl Microbiol Biotechnol 2012, 94:151-161.
62. Marusic C., Rizza P., Lattanzi L., Mancini C., Spada M., Belardelli F., et al. Chimeric plant virus particles as immunogens for inducing murine and human immune responses against human immunodeficiency virus type 1. J Virol 2001, 75:8434-8439.
63. Mehlotra R.K., Bockarie M.J., Zimmerman P.A. CYP2B6 983T>C polymorphism is prevalent in West Africa but absent in Papua New Guinea: implications for HIV/AIDS treatment. Br J Clin Pharmacol 2007, 64:391-395.
64. Miller L.H., Baruch D.I., Marsh K., Doumbo O.K. The pathogenic basis of malaria. Nature 2002, 415:673-679.
65. Miralpeix B., Rischer H., Hakkinen S.T., Ritala A., Seppanen-Laakso T., Oksman-Caldentey K.M., et al. Metabolic engineering of plant secondary products: which way forward?. Curr Pharm Des 2013, 19:5622-39.
66. Murray C.J.L., Rosenfeld L.C., Lim S.S., Andrews K.G., Foreman K.J., Haring D., et al. Global malaria mortality between 1980 and 2010: a systematic analysis. Lancet 2012, 379:413-431.
67. Nielsen N.O., Simonsen P.E., Magnussen P., Magesa S., Friis H. Cross-sectional relationship between HIV, lymphatic filariasis and other parasitic infections in adults in coastal northeastern Tanzania. Trans R Soc Trop Med Hyg 2006, 100:543-550.
68. Nobuyuki M., Husk A.S., Barnett B.W., Pickel M.M., Arntzen C.J., Montefiori D.C., et al. HIV-1 neutralization profile and plant-based recombinant expression of actinohivin, an Env glycan-specific lectin devoid of T-cell mitogenic activity. PLoS ONE 2010, 5:1.
69. O'Keefe B.R., Vojdani F., Buffa V., Shattock R.J., Montefiori D.C., Bakke J., et al. Scaleable manufacture of HIV-1 entry inhibitor griffithsin and validation of its safety and efficacy as a topical microbicide component. Proc Natl Acad Sci U S A 2009, 106:6099-6104.
70. Otieno R.O., Ouma C., Ong'echa J.M., Keller C.C., Were T., Waindi E.N., et al. Increased severe anemia in HIV-1-exposed and HIV-1-positive infants and children during acute malaria. AIDS 2006, 20:275-280.
71. Paddon C.J., Westfall P.J., Pitera D.J., Benjamin K., Fisher K., McPhee D., et al. High-level semi-synthetic production of the potent antimalarial artemisinin. Nature 2013, 496:528-32.
72. Patarroyo M.E., Bermúdez A., Moreno-Vranich A. Towards the development of a fully protective Plasmodium falciparum antimalarial vaccine. Expert Rev Vaccines 2012, 11:1057-70.
73. Patnaik P., Jere C.S., Miller W.C., Hoffman I.F., Wirima J., Pendame R., et al. Effects of HIV-1 serostatus, HIV-1 RNA concentration, and CD4 cell count on the incidence of malaria infection in a cohort of adults in rural Malawi. J Infect Dis 2005, 192:984-991.
74. Peplow M. Malaria drug made in yeast causes market ferment. Nature 2013, 494:160-161.
75. Quigley M.A., Hewitt K., Mayanja B., Morgan D., Eotu H., Ojwiya A., et al. The effect of malaria on mortality in a cohort of HIV-infected Ugandan adults. Trop Med Int Health 2005, 10:894-900.
76. Rademacher T., Sack M., Arcalis E., Stadlmann J., Balzer S., Altmann F., et al. Recombinant antibody 2G12 produced in maize endosperm efficiently neutralizes HIV-1 and contains predominantly single-GlcNAc N-glycans. Plant Biotechnol J 2008, 6:189-201.
77. Ramessar K., Capell T., Christou P. Molecular pharming in cereal crops. Phytochem Rev 2008, 7:579-592.
78. Ramessar K., Capell T., Twyman R.M., Quemada H., Christou P. Trace and traceability-a call for regulatory harmony. Nat Biotechnol 2008, 26:975-978.
79. Ramessar K., Rademacher T., Sack M., Stadlmann J., Platis D., Stiegler G., et al. Cost-effective production of a vaginal protein microbicide to prevent HIV transmission. Proc Natl Acad Sci USA 2008, 105:3727-3732.
80. Ramessar K., Sabalza M., Capell T., Christou P. Maize plants: An ideal production platform for effective and safe molecular pharming. Plant Sci 2008, 174:409-419.
81. Ramessar K., Capell T., Twyman R.M., Quemada H., Christou P. Calling the tunes on transgenic crops: the case for regulatory harmony. Mol Breed 2009, 23:99-112.
82. Ramessar K., Capell T., Twyman R.M., Christou P. Going to ridiculous lengths-European coexistence regulations for GM crops. Nat Biotechnol 2010, 28:133-136.
83. Ramirez Y.J.P., Tasciotti E., Gutierrez-Ortega A., Torres A.J.D., Flores M.T.O., Giacca M., et al. Fruit-specific expression of the human immunodeficiency virus type 1 Tat gene in tomato plants and its immunogenic potential in mice. Clin Vaccine Immunol 2007, 14:685-692.
84. Reina J.J., Bernardi A., Clerici M., Rojo J. HIV microbicides: state-of-the-art and new perspectives on the development of entry inhibitors. Future Med Chem 2010, 2:1141-1159.
85. Rischer H., Hakkinen S.T., Ritala A., Seppanen-Laakso T., Miralpeix B., Capell T., et al. Plant cells as pharmaceutical factories. Curr Pharm Des 2013, 19:5640-60.
86. Sabalza M., Madeira L., van Dolleweerd C., Ma J.K., Capell T., Christou P. Functional characterization of the recombinant HIV-neutralizing monoclonal antibody 2F5 produced in maize seeds. Plant Mol Biol 2012, 80:477-488.
87. Sabalza M., Vamvaka E., Christou P., Capell T. Seeds as a production system for molecular pharming applications: status and prospects. Curr Pharm Des 2013, 19:5543-52.
88. Sack M., Paetz A., Kunert R., Bomble M., Hesse F., Stiegler G., et al. Functional analysis of the broadly neutralizing human anti-HIV-1 antibody 2F5 produced in transgenic BY-2 suspension cultures. FASEB J 2007, 21:1655-1664.
89. Sexton A., Harman S., Shattock R.J., Ma J.K. Design, expression, and characterization of a multivalent, combination HIV microbicide. FASEB J 2009, 23:3590-3600.
90. Shors T. Understanding viruses 2011, Jones and Bartlett Publisher, Wisconsin. Second ed.
91. Soumare M., Seydi M., Diop S.A., Ba T.A., Ndour C.T., Dieng Y., et al. The place of malaria in an infectious disease department in Dakar, Senegal. Med Trop (Mars) 2008, 68:485-490.
92. Sparrow P., Broer I., Hood E.E., Eversole K., Hartung F., Schiemann J. Risk assessment and regulation of molecular farming-a comparison between Europe and US. Curr Pharm Des 2013, 19:5513-30.
93. Srivastava N., Akhila A. Biosynthesis of artemisinin - revisited. J Plant Interact 2011, 6:265-73.
94. Steketee R.W., Wirima J.J., Bloland P.B., Chilima B., Mermin J.H., Chitsulo L., et al. Impairment of a pregnant woman's acquired ability to limit Plasmodium falciparum by infection with human immunodeficiency virus type-1. Am J Trop Med Hyg 1996, 55:42-49.
95. Stoger E., Vaquero C., Torres E., Sack M., Nicholson L., Drossard J., et al. Cereal crops as viable production and storage systems for pharmaceutical scFv antibodies. Plant Mol Biol 2000, 42:583-590.
96. Stoger E., Sack M., Fischer R., Christou P. Plantibodies: applications, advantages and bottlenecks. Curr Opin Biotechnol 2002, 13:161-166.
97. Stoger E., Sack M., Perrin Y., Vaquero C., Torres E., Twyman R.M., et al. Practical considerations for pharmaceutical antibody production in different crop systems. Mol Breed 2002, 9:149-158.
98. Stoger E., Ma J.K., Fischer R., Christou P. Sowing the seeds of success: pharmaceutical proteins from plants. Curr Opin Biotechnol 2005, 16:167-173.
99. Stoger E., Sack M., Nicholson L., Fischer R., Christou P. Recent progress in plantibody technology. Curr Pharm Des 2005, 11:2439-2457.
100. Strasser R., Stadlmann J., Schahs M., Stiegler G., Quendler H., Mach L., et al. Generation of glyco-engineered Nicotiana benthamiana for the production of monoclonal antibodies with a homogeneous human-like N-glycan structure. Plant Biotechnol J 2008, 6:392-402.
101. Tang K., Shen Q., Yan T., Fu X. Transgenic approach to increase artemisinin content in Artemisia annua L. Plant Cell Rep 2014, [in press, published online ahead of print].
102. Ter Kuile F.O., Parise M.E., Verhoeff F.H., Udhayakumar V., Newman R.D., van Eijk A.M., et al. The burden of co-infection with human immunodeficiency virus type 1 and malaria in pregnant women in sub-Saharan Africa. Am J Trop Med Hyg 2004, 71:41-54.
103. Ticconi C., Mapfumo M., Dorrucci M., Naha N., Tarira E., Pietropolli A., et al. Effect of maternal HIV and malaria infection on pregnancy and perinatal outcome in Zimbabwe. J Acquir Immune Defic Syndr 2003, 34:289-294.
104. Troye-Blomberg M., Perlmann P., Mincheva Nilsson L., Perlmann H. Immune regulation of protection and pathogenesis in Plasmodium falciparum malaria. Parassitologia 1999, 41:131-138.
105. Turpen T.H., Reinl S.J., Charoenvit Y., Hoffman S.L., Fallarme V., Grill L.K. Malarial epitopes expressed on the surface of recombinant tobacco mosaic virus. Biotechnol 1995, 13:53-57.
106. Twyman R.M., Schillberg S., Fischer R. The production of vaccines and therapeutic antibodies in plants. Molecular farming in plants: recent advances and future prospects 2012, 145-159. Springer Netherlands.
107. van Eijk A.M., Ayisi J.G., Ter Kuile F.O., Misore A.O., Otieno J.A., Kolczak M.S., et al. Malaria and human immunodeficiency virus infection as risk factors for anemia in infants in Kisumu, western Kenya. Am J Trop Med Hyg 2002, 67:44-53.
108. van Herpen T.W., Cankar K., Nogueira M., Bosch D., Bouwmeester H.J., Beekwilder J. Nicotiana benthamiana as a production platform for artemisinin precursors. PLoS One 2010, 5:e14222.
109. Verhoeff F.H., Brabin B.J., Chimsuku L., Kazembe P., Russell W.B., Broadhead R.L. An evaluation of the effects of intermittent sulfadoxine-pyrimethamine treatment in pregnancy on parasite clearance and risk of low birth weight in rural Malawi. Ann Trop Med Parasitol 1998, 92:141-150.
110. Walton R.T., Rowland-Jones S.L. HIV and chemokine binding to red blood cells-DARC matters. Cell Host Microbe 2008, 4:3-5.
111. Wang L., Webster D.E., Campbell A.E., Dry I.B., Wesselingh S.L., Coppel R.L. Immunogenicity of Plasmodium yoelii merozoite surface protein 4/5 produced in transgenic plants. Int J Parasitol 2008, 38:103-110.
112. Webster D.E., Thomas M.C., Pickering R., Whyte A., Dry I.B., Gorry P.R., et al. Is there a role for plant-made vaccines in the prevention of HIV//AIDS?. Immunol Cell Biol 2005, 83:239-247.
113. Webster D.E., Wang L., Mulcair M., Ma C., Santi L., Mason H.S., et al. Production and characterization of an orally immunogenic Plasmodium antigen in plants using a virus-based expression system. Plant Biotechnol J 2009, 7:846-855.
114. Whitworth J., Morgen D., Quigley M., Smith A., Mayanja S., Eotu H., et al. Effect of HIV-1 and increasing immunosuppression on malaria parasitaemia and clinical episodes in adults in rural Uganda: a cohort study. Lancet 2000, 356:1051-1056.
115. Yuan D., Bassie L., Sabalza M., Miralpeix B., Dashevskaya S., Farre G., et al. The potential impact of plant biotechnology on the millennium development goals. Plant Cell Rep 2011, 30:249-265.
116. Yusibov V., Modelska A., Steplewski K., Agadjanyan M., Weiner D., Hooper D.C., et al. Antigens produced in plants by infection with chimeric plant viruses immunize against rabies virus and HIV-1. Proc Natl Acad Sci USA 1997, 94:5784-5788.
117. Zhang G.G., Rodrigues L., Rovinski B., White K.A. Production of HIV-1 p24 protein in transgenic tobacco plants. Mol Biotechnol 2002, 20:131-136.
118. Zhou X., Liu J., Yang B., Lin X., Yang X.W., Liu Y. Marine natural products with anti-HIV activities in the last decade. Curr Med Chem 2013, 20:953-73.
119. Zofou D., Ntie-Kang F., Sippl W., Efange S.M. Bioactive natural products derived from the Central African flora against neglected tropical diseases and HIV. Nat Prod Rep 2013, 30:1098-120.